Holly Stefl

Chief Executive Officer

Holly, CEO and Co-Founder of Attentive Science Australia Pty Ltd, brings over two decades of pharmaceutical and research expertise to her leadership role. Her extensive experience encompasses both nonclinical and clinical trials, as well as in-vitro drug metabolism, DDI studies, regulated bioanalysis and toxicology services across a range of species, reflecting her deep understanding of drug development on a global scale.

In her additional role as CCO at Endpoints Capital, Holly plays a pivotal role in providing non-dilutive R&D funding to biotechs, showcasing her strategic acumen in fostering innovation within the industry. Prior to this, her tenure as Chief Commercial Officer at Agilex Biolabs was marked by significant success, culminating in the company's acquisition by Healius Limited.

Holly's career journey has been characterized by various leadership positions, including roles at Quintiles phase I clinical research unit in Overland Park, Kansas, and as Director of Clinical Operations in a small oncology biotech. Her relocation to Sydney, Australia with IQVIA further broadened her expertise, enabling her to guide emerging biotechs across the US, EU, and APAC regions in navigating the complex landscape of conducting clinical trials in Australia.

Driven by her passion for improving patient outcomes, Holly is committed to bringing new life-transforming treatments to fruition. She prioritizes excellence in bioanalytical and toxicology services for new medicines, particularly where there aren’t any solutions and achieving successful clinical outcomes.

Alfred Botchway, PhD., DSP

Board Chair & Co-Founder

Dr. Alfred Botchway has over 25 years’ experience including academic, pharmaceutical and contract research organization tenure performing research studies designed to; investigate pharmacokinetic / pharmacodynamics profiles, minimize potential toxic and/or undesirable effects of agrochemical, biotechnological and pharmaceutical products on physiological functions prior to administration to the intended population. Dr. Botchway is the founder of Attetnive Science US and the co-founder of Attentive Science Australia Pty Ltd.  Alfred was the founder of Xenometrics a non-clinical contract research organization that provided pharmacokinetic, toxicological and safety pharmacology services to the biopharmaceutical and agrochemical industry. Subsequent to 12 years of successfully operating Xenometrics, Alfred exited Xenometrics a year after its sale to a multinational contract research organization. Dr. Botchway is an active member of several international scholastic professional scientific organizations. Alfred served as the President of the International Safety Pharmacology Society and continues to be an active Past President. Most recently, Alfred served as the interim President and Board Chair of BioKansas, a state trade organization for bioscience companies.Dr. Botchway holds a Ph.D. in Cardiovascular Physiology from Imperial College of Science, Technology and Medicine, University of London, UK., and a Diplomate in Safety Pharmacology from the Society of Safety Pharmacology.